Tvardi Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Tvardi Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- TVRD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001346830
Board of directors
-
Christopher Posner · Director · PRESIDENT AND CEOSince 2023
- Since 2025
-
Harrison M. Bains Jr. · DirectorSince 2023
-
Helen M. Boudreau · DirectorSince 2023
-
Imran Nizamudin Alibhai · Director · Chief Executive OfficerSince 2025
-
Jeffrey L. Ives · DirectorSince 2023
-
Martin Vogelbaum · DirectorSince 2023
-
Michael S. Wyzga · DirectorSince 2025
-
Moltke Lisa Von · DirectorSince 2023
-
Shaheen Wirk · DirectorSince 2025
-
Sujal Shah · DirectorSince 2025
-
Susan Shiff Ph.D. · DirectorSince 2023
-
Wallace L. Hall Jr. · DirectorSince 2025
Chief executives
Imran Nizamudin Alibhai
· Chief Executive Officer
Since April 2025
Christopher Posner
· President and CEO
Until April 2025
· Former
Board connections
5 of this board's directors also sit on 11 other boards.
- via Jeffrey L. Ives
- via Cynthia Smith
- via Cynthia Smith
- via Shaheen Wirk
- via Michael S. Wyzga
- via Michael S. Wyzga
- via Cynthia Smith
- via Helen M. Boudreau
- via Helen M. Boudreau
- via Cynthia Smith
- via Michael S. Wyzga
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 7, 2025 | Tweardy Samuel David 10% owner | Other | −315,658 | — | — |
| Jul 7, 2025 | Tweardy Samuel David 10% owner | Other | −315,658 | — | — |
| Apr 15, 2025 | Wallace L. Hall Jr. Director | Other | +44,712 | — | — |
| Apr 15, 2025 | Shaheen Wirk Director | Grant or award | +4,191 | — | — |
| Apr 15, 2025 | Wallace L. Hall Jr. Director | Other | +202,044 | — | — |
| Apr 15, 2025 | Shaheen Wirk Director | Other | +176,030 | — | — |
| Apr 15, 2025 | Shaheen Wirk Director | Other | +263,164 | — | — |
| Feb 28, 2025 | Christopher Posner Director, Officer (PRESIDENT AND CEO) | Open-market sale | −583 | $4.75 | $2,769 |
| Feb 28, 2025 | Terrillion Scott Officer (SEC'Y; CHIEF COMPLIANCE & G.C.) | Open-market sale | −163 | $4.76 | $776 |
| Feb 4, 2025 | Christopher Posner Director, Officer (PRESIDENT AND CEO) | Open-market sale | −372 | $4.72 | $1,756 |
| Nov 4, 2024 | Christopher Posner Director, Officer (PRESIDENT AND CEO) | Open-market sale | −3,668 | $0.29 | $1,064 |
| Aug 1, 2024 | Christopher Posner Director, Officer (PRESIDENT AND CEO) | Open-market sale | −4,149 | $0.35 | $1,452 |
| Jun 4, 2024 | Helen M. Boudreau Director | Grant or award | +150,647 | — | — |
| Jun 4, 2024 | Moltke Lisa Von Director | Grant or award | +150,647 | — | — |
| Jun 4, 2024 | Jeffrey L. Ives Director | Grant or award | +150,647 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.